PALO ALTO, Calif., November 14, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Joseph Pergolizzi, Jr., M.D. and Robert Raffa, Ph.D., will both present keynote speeches at the upcoming Pain Summit being held November 19-20th in Philadelphia, PA. With new non-opioid pain drugs demonstrating potential for a significant beneficial impact on the opioid crisis, each presentation will explore novel analgesic mechanisms and formulations currently in the research and development stages, including those that interact with adenosine-3 (A3) type receptors and novel IV approaches for acute post-surgical pain.
Details are as follows:
Joseph V. Pergolizzi, M.D.
Keynote Presentation Novel Analgesics: What’s New in Phases 1-3
Tuesday, November 19, 2019 at 9:30 – 10:00 am
Robert Raffa, Ph.D.
Keynote Presentation Explore the Next Generation of Analgesics Using Basic Science
Wednesday, November 20, 2019 at 9:15 – 10:00 am
The Pain Summit takes place at the Inn at Penn, A Hilton Hotel, 3600 Sansom Street Philadelphia, PA.
Addressing a National Health Emergency
Neumentum’s lead product candidate, NTM-001, may help address unmet needs for providers, payers and patients, offering effective pain treatment options without some of the potential disadvantages of opioids. Additionally, Neumentum recently acquired global rights to JNJ-10450232, a product that is neither an opioid nor a NSAID and has completed positive Phase 2A clinical studies for moderate to moderately severe acute pain. America’s opioid crisis has been declared a national public health emergency.
Over 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics. Yet opioids are associated with side effects – some severe enough to be treatment limiting – and the potential for misuse and abuse. While diversion of opioids is well publicized in the retail setting, it is also a growing problem in the hospital setting, where theft and illegal transfer have become increasingly prevalent.
Every day more than 1,000 people are treated in emergency rooms for misusing prescription opioids. There were more than 17,000 deaths due to prescription opioid pain relievers in 2015, nearly three times the number of deaths in 1999.
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company, with product candidates that have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids. Additionally, Neumentum recently acquired global rights to JNJ-10450232, a product that is neither an opioid nor a NSAID and has completed positive Phase 2A clinical studies for moderate to moderately severe acute pain. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization. For more information, visit Neumentum.com.
# # #
CEO & Co-founder
 Centers for Disease Control and Prevention, Prescription Opioid Overdose Data. https://www.cdc.gov/drugoverdose/data/overdose.html
 National Institute on Drug Abuse, Overdose Death Rates. Supporting data. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates